Centre for Cardiovascular Sciences, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Br J Pharmacol. 2013 Jun;169(3):659-70. doi: 10.1111/bph.12152.
Nitrite (NO₂⁻) has recently been shown to represent a potential source of NO, in particular under hypoxic conditions. The aim of the current study was to compare the haemodynamic effects of NO₂⁻ in healthy volunteers and patients with stable congestive heart failure (CHF).
The acute haemodynamic effects of brachial artery infusion of NO₂⁻ (0.31 to 7.8 μmol·min⁻¹) was assessed in normal subjects (n = 20) and CHF patients (n = 21).
NO₂⁻ infusion was well tolerated in all subjects. Forearm blood flow (FBF) increased markedly in CHF patients at NO₂⁻ infusion rates which induced no changes in normal subjects (ANOVA: F = 5.5; P = 0.02). Unstressed venous volume (UVV) increased even with the lowest NO₂⁻ infusion rate in all subjects (indicating venodilation), with CHF patients being relatively hyporesponsive compared with normal subjects (ANOVA: F = 6.2; P = 0.01). There were no differences in venous blood pH or oxygen concentration between groups or during NO₂⁻ infusion. Venous plasma NO₂⁻ concentrations were lower in CHF patients at baseline, and rose substantially less with NO₂⁻ infusion, without incremental oxidative generation of nitrate, consistent with accelerated clearance in these patients. Plasma protein-bound NO concentrations were lower in CHF patients than normal subjects at baseline. This difference was attenuated during NO₂⁻ infusion. Prolonged NO₂⁻ exposure in vivo did not induce oxidative stress, nor did it induce tolerance in vitro.
The findings of arterial hyper-responsiveness to infused NO₂⁻ in CHF patients, with evidence of accelerated transvascular NO₂⁻ clearance (presumably with concomitant NO release) suggests that NO₂⁻ effects may be accentuated in such patients. These findings provide a stimulus for the clinical exploration of NO₂⁻ as a therapeutic modality in CHF.
亚硝酸盐(NO₂⁻)最近被证明是一种潜在的一氧化氮(NO)来源,特别是在缺氧条件下。本研究旨在比较健康志愿者和稳定充血性心力衰竭(CHF)患者中亚硝酸盐的血液动力学效应。
评估了正常受试者(n=20)和 CHF 患者(n=21)中臂动脉输注亚硝酸盐(0.31 至 7.8 μmol·min⁻¹)的急性血液动力学效应。
亚硝酸盐输注在所有受试者中均耐受良好。CHF 患者在前臂血流量(FBF)在亚硝酸盐输注率下明显增加,而在正常受试者中没有变化(方差分析:F=5.5;P=0.02)。在所有受试者中,即使在最低的亚硝酸盐输注率下,未应激静脉容量(UVV)也明显增加(表明静脉扩张),与正常受试者相比,CHF 患者相对低反应性(方差分析:F=6.2;P=0.01)。在组间或亚硝酸盐输注期间,静脉血 pH 或氧浓度没有差异。CHF 患者的静脉血浆亚硝酸盐浓度在基线时较低,并且随着亚硝酸盐输注而显著升高,没有硝酸盐的额外氧化生成,这与这些患者的清除加速一致。CHF 患者的血浆蛋白结合型 NO 浓度在基线时低于正常受试者。这种差异在亚硝酸盐输注期间减弱。体内长时间暴露于亚硝酸盐不会引起氧化应激,也不会在体外引起耐受。
CHF 患者动脉对输注的亚硝酸盐的高反应性的发现,以及证据表明跨血管亚硝酸盐清除加速(推测伴有同时的 NO 释放)表明,NO₂⁻的作用可能在这些患者中更加明显。这些发现为临床探索 NO₂⁻作为 CHF 的治疗方法提供了动力。